SCHEMBL6165616

SCHEMBL6165616

COC(=O)c1cccc(-c2nnc(COC3CCCCO3)s2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 3/20 0.48
PDE4D Q08499 2/20 0.48
HRH3 Q9Y5N1 3/20 0.38
PDE4B Q07343 1/20 0.38
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167357 0.91 PDE7A (0.47) PDE7APDE4DHRH3PDE4BCPT2
SCHEMBL6168187 0.87 HRH3 (0.36) PDE7APDE4DHRH3ALDH1A1KDM4E
SCHEMBL6433928 0.83 CPT2 (0.48) PDE7APDE4DPDE4BCPT2CPT1A
SCHEMBL6163621 0.83 PDE7A (0.46) PDE7APDE4DPDE4BCPT2CPT1A
SCHEMBL6167701 0.81 NPC1 (0.44) PDE7APDE4DALDH1A1L3MBTL1POLB
SCHEMBL6167181 0.81 PDE7A (0.43) PDE7APDE4DPDE4BALDH1A1POLB
SCHEMBL6166540 0.81 PDE7A (0.44) PDE7APDE4DPDE4BCPT2CPT1A
SCHEMBL6167170 0.80 CPT2 (0.43) PDE7APDE4DPDE4BCPT2CPT1A
SCHEMBL5564507 0.79 PDE7A (0.41) PDE7APDE4DPDE4BKDM4EL3MBTL1
SCHEMBL6166557 0.79 CPT2 (0.41) PDE7APDE4DPDE4BCPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 PDE7A 1472/4885PDE4D 611/4885HRH3 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.